AFP and hepatocellular carcinoma: In the study cohort including 166 HCC patients with CPR and 332 control patients without HCC, the median AFP was 4.2 ng/mL (25–75 percentiles: 2.2–12.0) and 4.0 ng/mL (25–75 percentiles: 2.1–10.0), respectively (p = 0.596), and the median PIVKA-II was 20 mAU/mL (25–75 percentiles: 15–28) and 19 mAU/mL (25–75 percentiles: 12–31) respectively (p = 0.981; Figure 3).